Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel

Hepatology

Volumn 48, Issue 6, 2008, Pages 1779-1790

  Griffin, Stephen ^a   StGelais, Corine ^a   Owsianka, Ania M ^b   Patel, Arvind H ^b   Rowlands, David ^a   Harris, Mark ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b INSTITUTE OF VIROLOGY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; GSK 1 COMPOUND; GSK 2 COMPOUND; GSK 3 COMPOUND; HEXAMETHYLENE AMILORIDE; INTERCELLULAR ADHESION MOLECULE 1; J4 P7 PROTEIN; JFH 1 P7 PROTEIN; N NONYLDEOXYNOJIRIMYCIN; P7 ION CHANNEL; P7 ION CHANNEL INHIBITOR; RECOMBINANT PROTEIN; RIMANTADINE; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS PROTEIN; 1 DEOXYNOJIRIMYCIN; DRUG DERIVATIVE; N NONYL 1 DEOXYNOJIRIMYCIN; N-NONYL-1-DEOXYNOJIRIMYCIN; P7 PROTEIN, HEPATITIS C VIRUS;

ANTIVIRAL ACTIVITY; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG TARGETING; GENOTYPE; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN TARGETING; RNA REPLICATION; SEQUENCE ALIGNMENT; VIRION; VIRUS ENTRY; VIRUS INHIBITION; VIRUS REPLICATION; AMINO ACID SEQUENCE; CELL SURVIVAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HEPATITIS C; LIVER CELL CARCINOMA; LIVER TUMOR; MOLECULAR GENETICS; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

1-DEOXYNOJIRIMYCIN; AMANTADINE; AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; LIVER NEOPLASMS; MOLECULAR SEQUENCE DATA; RIMANTADINE; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 58149390243     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22555     Document Type: Article

References (40)

1. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. HEPATOLOGY 2006;43(2 Suppl 1):S207-S220.
2. Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, Muh U, Welker M, et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007;132: 1767-1777.
3. Moradpour D, Gosert R, Egger D, Penin F, Blum HE, Bienz K. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antiviral Res 2003;60:103-109.
4. Li XD, Sun L, Seth RB, Pineda G, Chen ZJ. Hepatitis C virus protease NS3/ 4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. Proc Natl Acad Sci U S A 2005;102: 17717-17722.
5. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004;85:2485-2502.
6. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, et al. Complete replication of hepatitis C virus in cell culture. Science 2005;309:623-626.
7. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005;11:791-796.
8. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, et al. Robust hepatitis C virus infection in vitro. Proc Natl Acad Sci U S A 2005;102:9294-9299.
9. Clarke D, Griffin S, Beales L, Gelais CS, Burgess S, Harris M, et al. Evidence for the formation of a heptameric ion channel complex by the hepatitis C virus p7 protein in vitro. J Biol Chem 2006;281:37057-37068.
10. Premkumar A, Wilson L, Ewart GD, Gage PW. Cation-selective ion channels formed by p7 of hepatitis C virus are blocked by hexamethylene amiloride. FEBS Lett 2004;557:99-103.
11. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, Fischer WB, et al. The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proc Natl Acad Sci U S A 2003;100:6104-6108.
12. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, Amantadine. FEBS Lett 2003;535:34-38.
13. Carrere-Kremer S, Montpellier-Pala C, Cocquerel L, Wychowski C, Penin F, Dubuisson J. Subcellular localization and topology of the p7 polypeptide of hepatitis C virus. J Virol 2002;76:3720-3730.
14. Mizushima H, Hijikata M, Asabe S, Hirota M, Kimura K, Shimotohno K. Two hepatitis C virus glycoprotein E2 products with different C termini. J Virol 1994;68:6215-6222.
15. Lin C, Lindenbach BD, Pragai BM, McCourt DW, Rice CM. Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini. J Virol 1994;68:5063-5073.
16. Griffin SD, Harvey R, Clarke DS, Barclay WS, Harris M, Rowlands DJ. A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria. J Gen Virol 2004;85:451-461.
17. Sakai A, Claire MS, Faulk K, Govindarajan S, Emerson SU, Purcell RH, et al. The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proc Natl Acad Sci U S A 2003;100:11646-11651.
18. Jones CT, Murray CL, Eastman DK, Tassello J, Rice CM. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007;81:8374-8383.
19. Steinmann E, Penin F, Kallis S, Patel AH, Bartenschlager R, Pietschmann T. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007;3:e103.
20. Haqshenas G, Mackenzie JM, Dong X, Gowans EJ. Hepatitis C virus p7 protein is localized in the endoplasmic reticulum when it is encoded by a replication-competent genome. J Gen Virol 2007;88:134-142.
21. Griffin S, Clarke D, McCormick C, Rowlands D, Harris M. Signal peptide cleavage and internal targeting signals direct the hepatitis C virus p7 protein to distinct intracellular membranes. J Virol 2005;79:15525-15536.
22. Deltenre P, Henrion J, Canva V, Dharancy S, Texier F, Louvet A, et al. Evaluation of amantadine in chronic hepatitis C: a meta-analysis. J Hepatol 2004;41:462-473.
23. St Gelais C, Tuthill TJ, Clarke DS, Rowlands DJ, Harris M, Griffin S. Inhibition of hepatitis C virus p7 membrane channels in a liposome-based assay system. Antiviral Res 2007;76:48-58.
24. Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985;4:3021-3024.
25. Steinmann E, Whitfield T, Kallis S, Dwek RA, Zitzmann N, Pietschmann T, Bartenschlager R. Antiviral effects of amantadine and iminosugar derivatives against hepatitis C virus. HEPATOLOGY 2007;46: 330-338.
26. Pietschmann T, Kaul A, Koutsoudakis G, Shavinskaya A, Kallis S, Steinmann E, et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci U S A 2006;103:7408-7413.
27. Targett-Adams P, McLauchlan J. Development and characterization of a transient-replication assay for the genotype 2a hepatitis C virus subgenomic replicon. J Gen Virol 2005;86:3075-3080.
28. Yanagi M, St Claire M, Shapiro M, Emerson SU, Purcell RH, Bukh J. Transcripts of a chimeric cDNA clone of hepatitis C virus genotype 1b are infectious in vivo. Virology 1998;244:161-172.
29. McCormick CJ, Maucourant S, Griffin S, Rowlands DJ, Harris M. Tagging of NS5A expressed from a functional hepatitis C virus replicon. J Gen Virol 2006;87:635-640.
30. Bartosch B, Dubuisson J, Cosset FL. Infectious hepatitis C virus pseudoparticles containing functional E1 - E2 envelope protein complexes. J Exp Med 2003;197:633-642.
31. McLauchlan J, Lemberg MK, Hope G, Martoglio B. Intramembrane proteolysis promotes trafficking of hepatitis C virus core protein to lipid droplets. EMBO J 2002;21:3980-3988.
32. Owsianka A, Clayton RF, Loomis-Price LD, McKeating JA, Patel AH. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J Gen Virol 2001;82:1877-1883.
33. Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem 2003;278:17775-17784.
34. Branza-Nichita N, Durantel D, Carrouee-Durantel S, Dwek RA, Zitzmann N. Antiviral effect of N-butyldeoxynojirimycin against bovine viral diarrhea virus correlates with misfolding of E2 envelope proteins and impairment of their association into E1 - E2 heterodimers. J Virol 2001;75:3527-3536.
35. Elbers K, Tautz N, Becher P, Stoll D, Rumenapf T, Thiel HJ. Processing in the pestivirus E2-NS2 region: identification of proteins p7 and E2p7. J Virol 1996;70:4131-4135.
36. Durantel D, Branza-Nichita N, Carrouee-Durantel S, Butters TD, Dwek RA, Zitzmann N. Study of the mechanism of antiviral action of iminosugar derivatives against bovine viral diarrhea virus. J Virol 2001; 75:8987-8998.
37. Pinto LH, Dieckmann GR, Gandhi CS, Papworth CG, Braman J, Shaughnessy MA, et al. A functionally defined model for the M2 proton channel of influenza A virus suggests a mechanism for its ion selectivity. Proc Natl Acad Sci U S A 1997;94:11301-11306.
38. Okada A, Miura T, Takeuchi H. Protonation of histidine and histidinetryptophan interaction in the activation of the M2 ion channel from influenza a virus. Biochemistry 2001;40:6053-6060.
39. Maynard M, Pradat P, Bailly F, Rozier F, Nemoz C, Si Ahmed SN, et al. Amantadine triple therapy for non-responder hepatitis C patients. Clues for controversies (ANRS HC 03 BITRI). J Hepatol 2006;44: 484-490.
40. Chan J, O'Riordan K, Wiley TE. Amantadine's viral kinetics in chronic hepatitis C infection. Dig Dis Sci 2002;47:438-442.